reports
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Oil & Oil Services Research
- Lars Trongaard Brattli
- Njål Kleiven
- ABGSC Oil & Oil Services Research
- Lars Trongaard Brattli
- Njål Kleiven
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Oil & Oil Services Research
- Lars Trongaard Brattli
- Njål Kleiven
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Oil & Oil Services Research
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
EQNR EQUINOR ASA
AKAST AKASTOR ASA
KOG KONGSBERG GRUPPEN ASA
SOC SUBSEA 7 S.A.
PEN PANORO ENERGY ASA
ARCHERO ARCHER
AKER AKER ASA CLASS A
DNO DNO ASA CLASS A
TGS TGS-NOPEC GEOPHYSICAL COMPANY ASA
ODL ODFJELL DRILLING
AKSOO AKER SOLUTIONS ASA
BWO BW OFFSHORE LIMITED
PRS PROSAFE
OKEA OKEA
BWE BW ENERGY
VAR VAR ENERGI ASA
SEAPT-NO SEACREST PETROLEO
DOFG DOF GROUP ASA
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 Sep...
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025 The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2025 Capital Markets Day.The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session.The purpose of the event is to give institutional investors and financial analysts an introductio...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
Avance Gas Holding Ltd: Special General Meeting – resolutions passed
Avance Gas Holding Ltd: Special General Meeting – resolutions passed Avance Gas Holding Ltd (the “Company”) advises that a Special General Meeting of the Shareholders of the Company (“SGM”) was held on 16 May 2025 at at 09:30 hrs, at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton, HM08, Bermuda, in relation to the proposed liquidation of the Company, appointing Mike Penrose of EY Bermuda Ltd. and Igal Wizman of EY Bahamas Ltd. as joint liquidators, and the delisting of the Company’s common shares from the Oslo Stock Exchange. Accordingly, the following resolutions were pa...
Avance Gas Holding Ltd: Change in Director Appointment
Avance Gas Holding Ltd: Change in Director Appointment Avance Gas Holding Ltd (“Avance Gas” or the "Company") announces that the Board of Directors has resolved to appoint James Ayers and Jonathan Burnett as Directors of the Company and accept the resignations of Øystein Kalleklev, Will Homan-Russell, François Sunier and Kathrine Fredriksen, all with immediate effect (“Directorship Changes”). James Ayers and Jonathan Burnett are currently CEO and CFO respectively of Front Ocean Management Ltd., a shared-service organization located in Bermuda, which provides various corporate and directors...
Coloplast AS: 1 director
A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Selskabsmeddelelse nr. 04/2025 - Regnskabsmeddelelse, ...
Coloplast A/S - Selskabsmeddelelse nr. 04/2025 - Regnskabsmeddelelse, 1. halvår 2024/25 Delårsrapport, første halvår 2024/25 1. oktober 2024 – 31. marts 2025 Coloplast leverede 6% organisk vækst i 2. kvartal, påvirket af produkttilbagekaldelsen i Urologi og et svagt kvartal i Stomi. Overskudsgraden1 i 2. kvartal holdt sig stabil på 27%. Den rapporterede omsætning målt i danske kroner steg 5%, påvirket af frasalget af hudplejeforretningen. Den organiske vækst pr. forretningsområde var 4% i Stomi, 8% i Kontinens, 7% i Stemme og Respiratorisk Pleje, 10% i Avanceret Sårpleje og -1% i Urol...
Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H...
Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25 Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostomy Care. Q2 EBIT margin1 held steady at 27%. Reported revenue in DKK grew 5%, impacted by the Skin Care divestment. Organic growth rates by business area: Ostomy Care 4%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 10% and Interventional Urology -1%.Growth in Chronic Care was driven ...
Coloplast A/S CEO Kristian Villumsen steps down as of today
Coloplast A/S CEO Kristian Villumsen steps down as of today Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy period, the Board of Directors has decided to initiate the search for a new CEO to lead Coloplast into its next phase of long-term, sustainable growth and value creation. As a result, President and CEO, Kristian Villumsen, steps down as of today. To ensure continuity, the Chair of the Board Lars Rasmussen assumes the role as...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.